300966.SZ
共同药业
SZSE · Healthcare · C 制造业 · CN
CNY 24.31
−3.42%Year over year
Reported trailing growth
- Revenue
- +13.6%
- EBITDA
- —
- EBIT
- -100.0%
- EPS
- —
- Free cash flow
- +89.8%
- Operating cash flow
- +378.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.1%
- EBITDA
- -34.9%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +62.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026